Folks, everyone in the world who can get their hands on an illumina sequencer is developing these "30 gene", "400 gene", "N gene" tests, liquid biopsies, blah, blah, blah. Even the fact that they got a VC to shell out $45M is something happen pretty regularly now. Source: senior pathology resident in San Diego, driving past illumina and the Craig Venter Institute every day. Developing these tests is literally all molecular pathologists do. All day long.
The game is to actually get a lot of patients. Memorial Sloan Kettering, Foundation One, Broad Institute, Venter are the biggest data-gatherers I'm aware of right now, with the DoD starting to get in the game. But who really wins will be the platforms that do the bioinformatics analysis: Google Genomics, illumina (basespace), etc.
And the ethics questions and "we don't know about the environment" questions aren't going to get answered until the data is collected. Wait till the EMRs are tied into the big data pipelines. Oh, nellie.
The game is to actually get a lot of patients. Memorial Sloan Kettering, Foundation One, Broad Institute, Venter are the biggest data-gatherers I'm aware of right now, with the DoD starting to get in the game. But who really wins will be the platforms that do the bioinformatics analysis: Google Genomics, illumina (basespace), etc.
And the ethics questions and "we don't know about the environment" questions aren't going to get answered until the data is collected. Wait till the EMRs are tied into the big data pipelines. Oh, nellie.